Literature DB >> 15015875

Clinical experience with MultiHance in CNS imaging.

M Essig1.   

Abstract

The use of Gd-BOPTA as a contrast agent for morphological and functional MR imaging allows improved detection and delineation of CNS lesions compared with conventional gadolinium agents. This not only leads to more confident diagnoses being made, but also results in a substantially improved differential diagnostic process. The higher relaxivity of Gd-BOPTA helps to optimize functional MR imaging studies, for example, perfusion MR imaging and dynamic MR angiographic protocols.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15015875     DOI： 10.1007/s00330-003-0001-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN： 0938-7994            Impact factor:   5.315


  31 in total

1.  Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine.

Authors:  D Balériaux; C Colosimo; J Ruscalleda; M Korves; G Schneider; K Bohndorf; G Bongartz; M A van Buchem; M Reiser; K Sartor; M W Bourne; P M Parizel; G R Cherryman; I Salerio; A La Noce; G Pirovano; M A Kirchin; A Spinazzi
Journal:  Neuroradiology       Date:  2002-03       Impact factor: 2.804

2.  MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

Authors:  W T Yuh; D J Fisher; J D Engelken; G M Greene; Y Sato; T J Ryals; M R Crain; J C Ehrhardt
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

3.  Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load.

Authors:  A Bozzao; R Floris; M E Baviera; A Apruzzese; G Simonetti
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

4.  MP-RAGE subtraction venography: a new technique.

Authors:  J Stevenson; E A Knopp; A W Litt
Journal:  J Magn Reson Imaging       Date:  1995 Mar-Apr       Impact factor: 4.813

5.  Interim results of phase II clinical testing of gadobenate dimeglumine.

Authors:  G Rosati; G Pirovano; A Spinazzi
Journal:  Invest Radiol       Date:  1994-06       Impact factor: 6.016

6.  Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging.

Authors:  Pamela W Schaefer; George J Hunter; Julian He; Leena M Hamberg; A Gregory Sorensen; Lee H Schwamm; Walter J Koroshetz; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

Review 7.  Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium.

Authors:  C de Haën; M Cabrini; L Akhnana; D Ratti; L Calabi; L Gozzini
Journal:  J Comput Assist Tomogr       Date:  1999-11       Impact factor: 1.826

8.  Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS.

Authors:  G Myhr; P A Rinck; A Børseth
Journal:  Acta Radiol       Date:  1992-09       Impact factor: 1.990

9.  Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.

Authors:  M Oudkerk; P E Sijens; E J Van Beek; T J Kuijpers
Journal:  Invest Radiol       Date:  1995-02       Impact factor: 6.016

10.  Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas. Effect of contrast medium extravasation.

Authors:  M Essig; F Wenz; R Scholdei; R Brüning; C Berchtenbreiter; M Meurer; M V Knopp
Journal:  Acta Radiol       Date:  2002-07       Impact factor: 1.701
View more
  1 in total

Review 1.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.

Authors:  Frederik L Giesel; Amit Mehndiratta; Marco Essig
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.